The stock of Vectura Group PLC (LON:VEC) is a huge mover today! The stock increased 2.33% or GBX 3.4 on November 18, hitting GBX 149.1. About 2.83M shares traded hands or 80.25% up from the average. Vectura Group PLC (LON:VEC) has declined 16.74% since April 19, 2016 and is downtrending. It has underperformed by 21.17% the S&P500.
The move comes after 8 months positive chart setup for the GBX 1.10B company. It was reported on Nov, 18 by Barchart.com. We have GBX 186.38 PT which if reached, will make LON:VEC worth GBX 275.00 million more.
Vectura Group PLC (LON:VEC) Ratings Coverage
Out of 8 analysts covering Vectura Group PLC (LON:VEC), 7 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 88% are positive. GBX 279 is the highest target while GBX 160 is the lowest. The GBX 215.38 average target is 44.45% above today’s (GBX 149.1) stock price. Vectura Group PLC has been the topic of 55 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus on Friday, January 8 with “Buy”. As per Monday, September 19, the company rating was maintained by Numis Securities. The company was maintained on Tuesday, March 1 by RBC Capital Markets. The firm earned “Overweight” rating on Monday, January 11 by JP Morgan. The firm earned “Buy” rating on Thursday, February 4 by Numis Securities. N+1 Singer maintained Vectura Group PLC (LON:VEC) on Thursday, January 28 with “Buy” rating. The company was reinitiated on Wednesday, July 6 by JP Morgan. The stock has “Overweight” rating given by JP Morgan on Monday, November 2. The stock of Vectura Group PLC (LON:VEC) has “Buy” rating given on Thursday, February 4 by Peel Hunt. The rating was maintained by Stifel Nicolaus on Friday, October 30 with “Buy”.
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The company has a market cap of 1.10 billion GBP. The Company’s products include Ultibro Breezhaler and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. It has a 130.45 P/E ratio. The Company’s product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.